跳至主要内容
临床试验/DRKS00015079
DRKS00015079已完成不适用

A prospective, non-interventional study to investigate the effectiveness of a recombinant fusion protein linking coagulation Factor IX with recombinant albumin (rIX-FP) in patients with hemophilia B

CSL Behring GmbH0 个研究点目标入组 73 人开始时间: 2018年8月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
73

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • Factor IX deficiency.
  • Treatment with IDELVION® according to routine practice and according to the current SmPC (The decision for IDELVION® therapy was made independent of this NIS)
  • Written and personally dated informed consent of the patient or in case of minors of one parent or legal guardian after receiving detailed information about the observational study by the treating physician. Minors should also sign the informed consent, if his/her age allows it.

排除标准

  • Existing inhibitor development.
  • Existing multi-factor-deficiency
  • simultaneous participation in an interventional study
  • Known hypersensitivity to any ingredient of the FIX product or hamster protein

研究者

相似试验